CTLA4 and neoplasm: Fc-dependent therapeutic efficacy of anti-CTLA-4 has similarly been demonstrated by several groups that observed reduced anti-tumor activity and Treg depletion when the Fc-domain is modified to exhibit lesser or no affinity for FcRs [26,28,67,68].